Gastrointestinal Pharmacology

Correct Answer

C — Chimeric (25% murine, 75% human) IgG1 anti-TNF-alpha monoclonal antibody given by intravenous infusion

Rationale

Infliximab is a chimeric monoclonal antibody — 25 percent murine and 75 percent human — that binds and neutralizes both soluble and membrane-bound TNF-alpha. It is administered by intravenous infusion at 5 mg/kg at weeks 0, 2, and 6 for induction, then every 8 weeks for maintenance. Its chimeric structure is clinically important because the murine component is immunogenic: anti-drug antibodies form against it and are the primary mechanism of secondary loss of response. Adalimumab is the fully human subcutaneous anti-TNF (option A); certolizumab pegol is the PEGylated Fab′ fragment without Fc region (option B); upadacitinib is the selective JAK1 inhibitor (option D).

Correct Answer

A — Certolizumab pegol

Rationale

Certolizumab pegol is classified as a PEGylated Fab′ fragment — it lacks the Fc region present in full monoclonal antibodies. Adalimumab, infliximab, and golimumab are all full IgG monoclonal antibodies targeting TNF-alpha.

Correct Answer

D — Alpha-4-beta-7 integrin

Rationale

Vedolizumab is classified as an alpha-4-beta-7 integrin antagonist. TNF-alpha is the target of infliximab, adalimumab, and other anti-TNF agents. The IL-12/IL-23 p40 subunit is the target of ustekinumab. JAK1 and JAK3 are targets of tofacitinib.

Correct Answer

B — Upadacitinib

Rationale

Upadacitinib is classified as a selective JAK1 inhibitor. Tofacitinib is a pan-JAK inhibitor with relative selectivity for JAK1 and JAK3. Ruxolitinib selectively inhibits JAK1 and JAK2 but is not approved for IBD. Baricitinib selectively inhibits JAK1 and JAK2 and is approved for rheumatoid arthritis and alopecia areata.

Correct Answer

C — The p40 subunit shared by interleukin-12 and interleukin-23

Rationale

Ustekinumab is classified as a monoclonal antibody targeting the p40 subunit shared by interleukin-12 and interleukin-23, blocking both cytokines simultaneously. Risankizumab selectively targets the IL-23 p19 subunit only. Vedolizumab targets the alpha-4-beta-7 integrin. TNF-alpha is the target of the anti-TNF agents.

Correct Answer

D — Increased risk of major adverse cardiovascular events, venous thromboembolism, and malignancy; use only after inadequate response to a TNF inhibitor

Rationale

The 2022 JAK inhibitor black box warning was prompted by the ORAL Surveillance post-marketing safety trial, which compared tofacitinib with TNF inhibitors in rheumatoid arthritis patients aged 50 or older with at least one cardiovascular risk factor. The trial found increased rates of major adverse cardiovascular events (MACE) including myocardial infarction and stroke, malignancy particularly lung cancer, and venous thromboembolism. The FDA applied the warning class-wide to all approved JAK inhibitors. The warning mandates: use only after inadequate response or intolerance to at least one TNF inhibitor; avoid in patients with known cardiovascular risk factors, active malignancy, or prior thromboembolism unless no adequate alternatives exist. Option A describes the hepatosplenic T-cell lymphoma risk associated with combined anti-TNF plus thiopurine therapy, not JAK inhibitors.

Correct Answer

A — Its chimeric structure contains 25 percent murine-sequence protein that the human immune system can recognize as foreign and generate antibodies against

Rationale

Immunogenicity in biologic therapy is driven by the presence of non-self protein sequences. Infliximab's variable regions — which include the antigen-binding portion — are derived from mouse antibodies, comprising approximately 25 percent of the molecule. The human immune system can recognize these murine sequences as foreign epitopes and mount an antibody response against them, generating anti-drug antibodies (ADA). These ADA bind infliximab and accelerate its clearance, reducing trough concentrations and causing secondary loss of response. Adalimumab is fully human in sequence, presenting no foreign epitopes, and therefore has substantially lower immunogenicity. Co-administration of azathioprine or 6-mercaptopurine reduces ADA formation for both agents but particularly benefits infliximab because of its higher baseline immunogenicity.

Correct Answer

B — TNF-alpha is essential for maintaining granuloma integrity; neutralizing TNF-alpha releases viable mycobacteria from quiescent granulomas, causing reactivation tuberculosis

Rationale

The tuberculosis reactivation risk of anti-TNF therapy is a direct consequence of TNF-alpha's immunological role. TNF-alpha is a critical cytokine for granuloma formation and maintenance — it recruits macrophages, promotes their activation, and sustains the organized structure that walls off Mycobacterium tuberculosis in latent infection. Neutralizing TNF-alpha with anti-TNF biologics disrupts granuloma integrity, releasing viable mycobacteria that had been contained for years or decades. The result is reactivation tuberculosis, often disseminated. This risk is class-wide for all anti-TNF agents and requires tuberculin skin test or IGRA plus chest X-ray before starting; latent tuberculosis must be treated for at least 4 weeks before initiating the biologic. Vedolizumab, which does not affect systemic TNF-alpha levels, does not carry this reactivation risk and does not require TB screening.

Correct Answer

D — Hepatosplenic T-cell lymphoma — a rare but almost universally fatal malignancy reported almost exclusively in young males on long-term combined anti-TNF plus thiopurine therapy

Rationale

Hepatosplenic T-cell lymphoma (HSTCL) is a rare but devastatingly lethal malignancy of gamma-delta T cells that has been reported almost exclusively in young males (typically under age 35) receiving long-term combination therapy with an anti-TNF agent and a thiopurine. The mechanism is not fully characterized but likely reflects profound impairment of T-cell immune surveillance from the combined immunosuppressive burden — anti-TNF blockade plus thiopurine-mediated lymphocyte DNA damage — that allows clonal expansion of malignant T cells. Because of this risk, guidelines recommend that after 2 years of combination therapy in patients who have achieved deep remission, withdrawal of the thiopurine while continuing the biologic is a reasonable strategy to reduce cumulative immunosuppressive exposure. This risk-benefit consideration is an important part of long-term IBD management planning.

Correct Answer

C — By blocking alpha-4-beta-7 integrin expressed predominantly on gut-homing lymphocytes, vedolizumab compartmentalizes immunosuppression to the gut while leaving systemic immune surveillance largely intact

Rationale

The alpha-4-beta-7 integrin targeted by vedolizumab is expressed predominantly on lymphocytes that home specifically to the gut mucosa, not on systemic circulating lymphocytes that patrol peripheral tissues, lymph nodes, and lungs. Blocking this integrin prevents gut-homing lymphocytes from trafficking to the intestinal mucosa, producing local immunosuppression in the bowel wall. Systemic lymphocytes — which use different integrins for tissue trafficking — are largely unaffected. The practical consequence is that large post-marketing datasets show no increase in systemic serious infections, and latent tuberculosis screening is not required. Anti-TNF agents, by contrast, deplete TNF-alpha systemically, impairing granuloma maintenance throughout the body and increasing systemic infection risk including tuberculosis, invasive fungal infections, and opportunistic bacterial infections.

Correct Answer

B — Switch to a different anti-TNF agent or a different biologic class, because high anti-drug antibodies indicate immunogenic failure that dose escalation of infliximab will not overcome

Rationale

Therapeutic drug monitoring distinguishes three mechanisms of loss of response, each requiring a different management approach. This patient has high anti-drug antibodies with a low trough — the pattern of immunogenic failure. Anti-drug antibodies bind infliximab and neutralize it and accelerate its clearance; increasing the dose simply provides more substrate for the same antibody-mediated clearance and does not restore therapeutic trough concentrations. The correct response to immunogenic failure is switching to a different anti-TNF agent (adalimumab or certolizumab — antibodies against infliximab's murine component do not cross-react with fully human agents) or switching to a completely different biologic class (vedolizumab, ustekinumab). Adding azathioprine to prevent future ADA formation is a reasonable adjunct, but it does not reliably reverse already-established high-titer ADA.

Correct Answer

A — JAK inhibitors are oral small molecules with reliable bioavailability and rapid onset of action within days; biologics require intravenous or subcutaneous administration and have slower onsets

Rationale

As small molecules, JAK inhibitors have two key pharmacokinetic advantages over large-protein biologics. First, oral bioavailability: small molecules cross intestinal epithelial cells readily, while large proteins like monoclonal antibodies cannot survive oral administration and must be injected. Second, rapid onset: JAK inhibitors produce measurable anti-inflammatory effects within days of starting because they directly inhibit intracellular signaling enzymes; biologics exert their effects more gradually as antibody levels build after induction dosing. Option D is also true — JAK inhibitors do not generate immunogenicity because they are small non-protein molecules — but it is a pharmacodynamic rather than pharmacokinetic advantage and was not the best answer in the context of the question. The lack of immunogenicity means no therapeutic drug monitoring for anti-drug antibodies is needed.

Correct Answer

C — Pharmacodynamic failure — TNF-alpha is adequately blocked but is not the dominant driver of this patient's mucosal inflammation; a different biologic class is needed

Rationale

The therapeutic drug monitoring framework distinguishes three loss-of-response patterns. An adequate trough concentration with no clinical response is pharmacodynamic failure — the drug is present at sufficient levels to block TNF-alpha, but TNF-alpha blockade alone is insufficient to control inflammation in this patient. This indicates that alternative cytokine pathways (IL-23, alpha-4-beta-7-mediated lymphocyte trafficking, JAK-STAT signaling) are the dominant mediators of disease in this individual. The correct management is switching to a different biologic class — vedolizumab, ustekinumab, risankizumab, or a JAK inhibitor — not dose escalation of infliximab. Escalating the dose of infliximab when trough concentrations are already adequate provides no additional target blockade and exposes the patient to additional immunosuppression without therapeutic benefit.

Correct Answer

D — JAK inhibitors suppress cytokine signaling through the common gamma chain cytokine receptors that are essential for T-cell-mediated control of varicella-zoster virus reactivation from dorsal root ganglia

Rationale

Varicella-zoster virus establishes lifelong latency in sensory dorsal root ganglia. Control of reactivation depends on CD8+ T-cell immune surveillance, which is maintained by cytokine signaling through the common gamma chain (gamma-c) cytokine receptors — particularly IL-2, IL-7, and IL-15 receptors. These receptors signal through JAK1 and JAK3. JAK inhibitors block this signaling pathway, impairing CD8+ T-cell survival, proliferation, and activation. The reduced T-cell surveillance allows varicella-zoster virus to reactivate from its neural latency and spread along the dermatome, causing herpes zoster. This risk is substantially higher with JAK inhibitors than with anti-TNF or gut-selective biologics, which do not interfere with the common gamma chain cytokine signaling that sustains antiviral T-cell immunity. Recombinant zoster vaccine is recommended before or shortly after starting JAK inhibitor therapy.

Correct Answer

A — Vedolizumab, because its alpha-4-beta-7 integrin blockade compartmentalizes immunosuppression to the gut, leaving systemic immune surveillance intact and minimizing systemic infection risk

Rationale

This elderly patient with recurrent infections represents exactly the population for whom vedolizumab's gut-selective mechanism is clinically important. Anti-TNF agents systemically deplete TNF-alpha, impairing granuloma maintenance and increasing the risk of serious systemic infections including tuberculosis reactivation, invasive fungal infections, and bacterial pneumonia — risks that are amplified in elderly and already infection-prone patients. Vedolizumab's alpha-4-beta-7 blockade limits immunosuppression to gut-homing lymphocyte trafficking without affecting systemic immune surveillance; large post-marketing datasets confirm no increase in serious systemic infections. JAK inhibitors (option C) carry the 2022 black box warning for MACE and malignancy and are second-line after TNF inhibitor failure, making them inappropriate as initial therapy here. Ustekinumab is also a reasonable option but has a less well-established gut-selective infection advantage compared with vedolizumab.

Correct Answer

B — Certolizumab pegol, because it lacks the Fc region and does not undergo neonatal Fc receptor-mediated placental transfer, resulting in negligible fetal drug concentrations

Rationale

Active placental transfer of IgG antibodies increases substantially after 22 weeks of gestation, mediated by the neonatal Fc receptor on syncytiotrophoblast cells. By 26 weeks, this patient is in a period of active antibody transfer. Infliximab and adalimumab — both intact IgG1 molecules — are actively transported across the placenta via the FcRn and achieve measurable fetal concentrations that persist for 6 months after birth, during which time live vaccines must be avoided in the infant. Certolizumab pegol lacks the Fc region entirely and therefore has no substrate for FcRn-mediated transport; pharmacokinetic studies demonstrate negligible cord blood and infant drug concentrations. When anti-TNF therapy is required in the third trimester, certolizumab pegol is the agent of choice for this reason. Option C is incorrect: adalimumab is a fully human IgG1 and does cross the placenta via FcRn — the neonatal Fc receptor transports IgG regardless of species origin.

Correct Answer

D — The 2022 FDA black box warning identifies increased MACE risk with tofacitinib in patients with cardiovascular risk factors; this patient's prior MI, hypertension, and hyperlipidemia place him in the high-risk group the warning specifically targets

Rationale

The 2022 FDA black box warning for JAK inhibitors was derived from the ORAL Surveillance trial, which found increased rates of MACE — including myocardial infarction and stroke — with tofacitinib compared with TNF inhibitors in patients aged 50 or older with at least one cardiovascular risk factor. This patient has multiple cardiovascular risk factors (prior MI, hypertension, hyperlipidemia) and is aged 58, placing him squarely in the population the trial enrolled and the warning specifically addresses. The FDA warning states JAK inhibitors should be avoided in patients with known cardiovascular risk factors when adequate alternatives exist. After two anti-TNF failures, switching to vedolizumab or ustekinumab — which carry no cardiovascular black box warning — is the appropriate strategy before considering a JAK inhibitor, and only if those alternatives also fail would the benefit-risk calculation for tofacitinib potentially favor its use with careful patient counseling.

Correct Answer

C — Pharmacodynamic failure — TNF-alpha is adequately blocked but is not the dominant inflammatory mediator in this patient; switch to a different biologic class

Rationale

The combination of adequate trough concentration and undetectable anti-drug antibodies with persistent loss of response defines pharmacodynamic failure in the therapeutic drug monitoring framework. Drug is present at sufficient levels; immunogenicity is not the mechanism; yet disease remains active. The logical conclusion is that TNF-alpha blockade is not sufficient to control this patient's Crohn's disease — either because the dominant inflammatory pathways in his disease are mediated by cytokines other than TNF-alpha (IL-23, IL-12, alpha-4-beta-7-mediated trafficking) or because TNF-alpha is a contributory but not rate-limiting driver. Dose escalation of infliximab would intensify blockade of a target that is already adequately blocked, providing no therapeutic benefit while adding cost and risk. The correct intervention is switching to a mechanistically different biologic class — vedolizumab, ustekinumab, or risankizumab — to address the alternative inflammatory pathways driving his disease.